In one study, tumor progression in mid- to late-stage, somatostatin inhibitor receptor-positive patients is effectively blocked by lanreotide, providing good symptom control [31] Molecular target therapy is based on gene mutations widely found in PNETs. This evidence concerns the gene SST and neoplasm.